IceCure Medical : January 2023

Freezing cancer in its tracks

IceCure Medical enabling non‐surgical, treatment of cancerous tumors

Corporate Presentation | January 2023

(NASDAQ & TASE: ICCM) icecure-medical.com

Nasdaq & TASE: ICCM

Forward Looking Statement

Disclaimer:

IMPORTANT: The following applies to this document, the oral presentation of the information in this document by IceCure Medical Ltd. (the "Company", "we" or "us") and any question-and- answer session that will follow the oral presentation (collectively, the "Presentation"). This Presentation contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. For example, we are using forward-looking statements when we discuss our regulatory, marketing and commercialization strategy, the expected timing of obtaining regulatory approval for our various products, patient trials and clinical data readout, proposed trials that may occur in the future, the timing and implementation of our collaborations with various partners and the execution of definitive agreements relating to such collaborations and the potential benefits and impact our products could have on improving patient health care. These forward-looking statements and their implications are based on the current expectations of our management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may be more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting us, reference is made to our reports filed from time to time with the U.S. Securities and Exchange Commission.

This Presentation does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase securities of the Company or any other entity, and nothing contained herein shall form the basis of or be relied on in connection with any action, contract, commitment or relating thereto or to the securities of the Company.

No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Presentation. The Presentation has not been independently verified and will not be updated. The Presentation, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results.

Nasdaq & TASE: ICCM

2

Introducing ProSense®

Non-surgicalNext-Generation Cryoablation

Technology

Cryoablation is a minimally invasive image guided (US or CT) treatment that uses extreme cold to freeze and accurately destroy diseased tissue within the tumor zone

IceCure's flagship product ProSense® cryoablates tumors quickly and with minimal pain*

Utilizing effective liquid nitrogen (LN2) for maximum freezing, safety and efficacy

http://www.youtube.com/watch?v=TfhQJ3SN6wQ

* freezing effect on tissue from cryoablation produces less pain compared to heat ablation

Nasdaq & TASE: ICCM

3

Company Highlights

ICE3 Breast Cancer Trial	Regulatory approval in 15*	Growing number of	Wide market applications
countries including EU & US
$2.4 B tumor ablation market
in US for FDA approval in treating	FDA Clearance;	global distribution
by 2028 †
early-stage breast tumors	Filed FDA De Novo for	agreements
	early-stagelow-risk breast
	cancer patients at high
	risk to surgery

Collaboration with	Reimbursement: CPT III	29 patents in IP	Successful	Excellent Patient
ASBrS for registry trial	for breast cancer	portfolio for advanced	transition from
and update of	cryoablation facility fee	LN2 technology	clinical and R&D	& Physician
guidelines	established		stages to	Feedback
	commercialization

*China - system only; Brazil - cryoprobes and introducers only †Estimated, according to Grand View Research, Inc. (www.grandviewresearch.com/industry-analysis/tumor-ablation-market) Data is for all tumor ablation technologies and indications, including heat ablation Cryoablation, RF, MW and others. The information herein has not been independently verified by the company

Nasdaq & TASE: ICCM

4

Market Opportunities

Tumor Ablation

Tumor Ablation Market Expected To Reach

$2.4 Billion in 2028†

	$2.4B	(CAGR)
		Potential driven
		by non/minimal
		invasive
$1.0B		treatments such
	as
2021	2028	Cryoablation†
Growing	Increasing demand	Push for reduced
cancer	for non/minimal-	cost of care by
burden	invasive solutions	insurers and payers

†Estimated, according to Grand View Research, Inc. (www.grandviewresearch.com/industry-analysis/tumor-ablation-market) Data is for all tumor ablation technologies and indications, including heat ablation Cryoablation, RF, MW and others. The information herein has not been independently verified by the company

US Cryoablation

Breast Tumors

• Targeting ~288K new invasive breast cancer patients estimated in 2022*
• 10% of female pop. est. to have fibroadenomas**

Breast Cancer

Breast Fibroadenoma

Interventional Radiology

118K New kidney and liver cancer patients in 2021*

Kidney	Lung	Bone	Additional	Liver
Cancer	Cancer	Cancer	future indications

(Such as Prostate Cancer)

• American Cancer Society - About Breast Cancer. -https://www.cancer.org/content/dam/CRC/PDF/Public/8577.00.pdf

**https://www.ncbi.nlm.nih.gov/books/NBK535345/#article-18600.s6

Nasdaq & TASE: ICCM

5